Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab

Alexander Zink*, Anna Gensbaur, Michael Zirbs, Florian Seifert, Isabel Leon Suarez, Vagkan Mourantchanian, Stephan Weidinger, Martin Mempel, Johannes Ring, Markus Ollert

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)

Abstract

Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti- IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.

Original languageEnglish
Pages (from-to)72-76
Number of pages5
JournalActa Dermato-Venereologica
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 2016
Externally publishedYes

Keywords

  • Anti-IgE-treatment
  • Atopic dermatitis
  • Atopic eczema
  • IgE
  • Immunoadsorption
  • Immunoglobulin E
  • Omalizumab

Fingerprint

Dive into the research topics of 'Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab'. Together they form a unique fingerprint.

Cite this